BIOTRONIK - A Prospective Multicenter Single Arm Study to Assess the SaFety and Effectiveness of the Orsiro Mission 48-mm SiroLimus-Eluting Coronary Stent System for the Treatment Of Subjects With Atherosclerotic Lesion(s)
Latest Information Update: 02 Apr 2026
At a glance
- Drugs Sirolimus (Primary)
- Indications Coronary artery disease; Stent thrombosis
- Focus Therapeutic Use
- Acronyms BIOFLOW-48
- Sponsors BIOTRONIK
Most Recent Events
- 25 Jul 2025 Status changed from not yet recruiting to recruiting.
- 24 Jan 2025 New trial record